Amgen Inc. (ETR:AMG)

Market Cap	154.95B +10.3%
Revenue (ttm)	30.66B +10.6%
Net Income	5.97B +65.6%
EPS	11.02 +65.1%
Shares Out	n/a
PE Ratio	25.95
Forward PE	16.20
Dividend	8.52 (2.99%)
Ex-Dividend Date	Nov 21, 2025

Volume	1,432
Average Volume	717
Open	285.15
Previous Close	287.30
Day's Range	284.60 - 288.50
52-Week Range	230.00 - 308.50
Beta	0.45
RSI	51.81
Earnings Date	Feb 3, 2026

About Amgen

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascul...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1980
• Employees: 28,000
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: AMG

Financial Performance

In 2024, Amgen's revenue was $33.42 billion, an increase of 18.57% compared to the previous year's $28.19 billion. Earnings were $4.09 billion, a decrease of -39.11%.

Financial numbers in USD